Anthony Sebba

2.9k total citations · 1 hit paper
37 papers, 2.0k citations indexed

About

Anthony Sebba is a scholar working on Rheumatology, Oncology and Orthopedics and Sports Medicine. According to data from OpenAlex, Anthony Sebba has authored 37 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Rheumatology, 15 papers in Oncology and 14 papers in Orthopedics and Sports Medicine. Recurrent topics in Anthony Sebba's work include Rheumatoid Arthritis Research and Therapies (21 papers), Bone health and osteoporosis research (14 papers) and Bone health and treatments (13 papers). Anthony Sebba is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (21 papers), Bone health and osteoporosis research (14 papers) and Bone health and treatments (13 papers). Anthony Sebba collaborates with scholars based in United States, United Kingdom and Australia. Anthony Sebba's co-authors include Juan J. Gómez‐Reino, Graeme Jones, M. C. Genovese, Jianhui Gu, Matija Tomšič, Andrea Calvo, Mitchell B. Lowenstein, Daniel Siri, Thasia Woodworth and Emma Alecock and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Journal of Bone and Mineral Research and Annals of the Rheumatic Diseases.

In The Last Decade

Anthony Sebba

37 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

2009 609 citations Graeme Jones, Anthony Sebba et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anthony Sebba United States	19	973	493	456	397	387	37	2.0k
Edmund K. Li Hong Kong	31	1.7k 1.7×	237 0.5×	311 0.7×	1.0k 2.6×	208 0.5×	75	2.6k
J Rovenský Slovakia	15	1.4k 1.4×	222 0.5×	585 1.3×	534 1.3×	83 0.2×	47	2.2k
Dorothy McCabe United States	17	1.3k 1.4×	362 0.7×	706 1.5×	896 2.3×	70 0.2×	37	2.5k
Piet Geusens Belgium	26	1.3k 1.4×	406 0.8×	154 0.3×	505 1.3×	834 2.2×	66	2.7k
Hennie G. Raterman Netherlands	22	679 0.7×	198 0.4×	109 0.2×	216 0.5×	276 0.7×	40	1.5k
Chin Teck Ng Malaysia	23	823 0.8×	183 0.4×	293 0.6×	530 1.3×	74 0.2×	49	1.9k
Leo B. A. Van De Putte Netherlands	18	1.4k 1.4×	227 0.5×	378 0.8×	615 1.5×	41 0.1×	34	2.6k
Simon M. Helfgott United States	22	682 0.7×	148 0.3×	207 0.5×	323 0.8×	38 0.1×	46	1.5k
Solveig Wållberg‐Jonsson Sweden	24	1.8k 1.8×	136 0.3×	320 0.7×	446 1.1×	35 0.1×	50	2.5k
Alejandro Escudero‐Contreras Spain	21	994 1.0×	70 0.1×	361 0.8×	581 1.5×	73 0.2×	122	1.6k

Countries citing papers authored by Anthony Sebba

Since Specialization

Citations

This map shows the geographic impact of Anthony Sebba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Sebba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Sebba more than expected).

Fields of papers citing papers by Anthony Sebba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Sebba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Sebba. The network helps show where Anthony Sebba may publish in the future.

Co-authorship network of co-authors of Anthony Sebba

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Sebba. A scholar is included among the top collaborators of Anthony Sebba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Sebba. Anthony Sebba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rohekar, Sherry, Aisha Vadhariya, Sarah J. Ross, et al.. (2024). Real‐World Treatment Patterns, Clinical Outcomes, and Symptom Burden in Patients With Psoriatic Arthritis Prescribed Ixekizumab in the United States. ACR Open Rheumatology. 6(7). 440–449. 1 indexed citations

Sebba, Anthony, Clifton O. Bingham, Vivian P. Bykerk, et al.. (2023). Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Clinical Rheumatology. 42(8). 2037–2051. 4 indexed citations

Sebba, Anthony. (2021). Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis. Open Access Rheumatology Research and Reviews. Volume 13. 31–43. 51 indexed citations

Smolen, Josef S, Anthony Sebba, Eric Ruderman, et al.. (2020). Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. Rheumatology and Therapy. 7(4). 1021–1035. 27 indexed citations

Jones, Graeme, Thomas W. Wallace, Matthew J. McIntosh, et al.. (2016). Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study. The Journal of Rheumatology. 44(2). 142–146. 29 indexed citations

Silverman, Stuart L., Paul D. Miller, Anthony Sebba, et al.. (2013). The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporosis International. 24(8). 2309–2317. 42 indexed citations

Emery, Paul, Anthony Sebba, & T. Huizinga. (2013). Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Annals of the Rheumatic Diseases. 72(12). 1897–1904. 106 indexed citations

Ricca, Louis, et al.. (2012). A safety analysis of oral prednisone as a pretreatment for rituximab in rheumatoid arthritis. Clinical Rheumatology. 31(11). 1605–1610. 6 indexed citations

Alten, Rieke, Juan J. Gómez‐Reino, Patrick Durez, et al.. (2011). Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskeletal Disorders. 12(1). 153–153. 114 indexed citations

10.

Jones, Graeme, Anthony Sebba, Jianhui Gu, et al.. (2009). Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases. 69(1). 88–96. 609 indexed citations breakdown →

11.

Stoch, S. Aubrey, Kenneth G. Saag, Maria Greenwald, et al.. (2009). Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial. The Journal of Rheumatology. 36(8). 1705–1714. 75 indexed citations

12.

Sebba, Anthony. (2008). Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Clinical Therapeutics. 30(3). 443–452. 36 indexed citations

13.

Sebba, Anthony. (2008). Osteoporosis: how long should we treat?. Current Opinion in Endocrinology Diabetes and Obesity. 15(6). 502–507. 18 indexed citations

14.

Sebba, Anthony, Susan B. Broy, Joseph D. Kohles, & Peter N. Weissman. (2008). Rapid Suppression of Bone Resorption Marker Levels With Ibandronate Therapy in a Bisphosphonate-Naïve Population. Journal of Clinical Densitometry. 11(3). 417–423. 6 indexed citations

15.

Sebba, Anthony. (2008). Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface. Osteoporosis International. 20(5). 675–686. 13 indexed citations

16.

Bonnick, Sydney Lou, Kenneth G. Saag, Douglas P. Kiel, et al.. (2006). Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years. Obstetrical & Gynecological Survey. 62(1). 35–36. 5 indexed citations

17.

Bingham, Clifton O., Anthony Sebba, Gary Ruoff, et al.. (2006). Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Lara D. Veeken. 46(3). 496–507. 94 indexed citations

18.

Bonnick, Sydney Lou, Kenneth G. Saag, Douglas P. Kiel, et al.. (2006). Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years. The Journal of Clinical Endocrinology & Metabolism. 91(7). 2631–2637. 105 indexed citations

19.

Sebba, Anthony, Sydney Lou Bonnick, Risa Kagan, et al.. (2004). Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Current Medical Research and Opinion. 20(12). 2031–2041. 44 indexed citations

20.

Sebba, Anthony. (2001). Alendronate for Osteoporosis. 12(1). 319. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact